Gillian McGovern, Editor

The authors note that further research is needed to clarify cost-effectiveness, long-term adherence, and psychosocial impacts of oral immunotherapy.

Some of these approaches for chronic kidney disease (CKD) include cystatin C, SGLT2 inhibitors, point-of-care testing in remote areas, and acid-lowering medications.

Untargeted lipidomics identified a glycerophospholipid and sphingolipid signature that differentiated severe alcohol-related hepatitis (sAH) from decompensated cirrhosis (DC).

Although the 16-week end point was not met, tezepelumab demonstrated meaningful effects in patients with chronic spontaneous urticaria (CSU) after 32 weeks.

Although improvements were observed in blood pressure (BP) medication adherence, there were no improvements in stain or glucose-lowering medication use.

Currently, EN001 is undergoing evaluation in a phase 1b trial.

The cancers linked with per- and polyfluoroalkyl substance (PFAS) exposure included nonastrocytoma gliomas, acute myeloid leukemia, and Wilms tumors.

The treatment is currently undergoing evaluation in an investigational preclinical program and is projected to be in human trials in 2026.

The treatment's expanded indication for chronic kidney disease (CKD) is expected to be available by April 2025.

The approval is based on results from 2 phase 3 clinical trials that showed revakinagene taroretcel’s efficacy in macular telangiectasia type 2 (MacTel).

The move is expected to expand clozapine access for patients with schizophrenia.

Pharmacists also educate, advocate, and ensure patients with heart failure with reduced ejection fraction (HFrEF) and anemia are receiving the appropriate regimens.

Tezepelumab demonstrated efficacy compared with placebo when treating patients with chronic rhinosinusitis with nasal polyps.

The designation was granted after positive results from the phase 1 STOMP-I clinical trial (NCT01915927).

The action follows pooled data from 2 studies that enrolled patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still disease.

Additional risk factors included older age and advanced chronic kidney disease (CKD) stage.

In a clinical trial, tenecteplase was shown to be a comparable alternative to alteplase.

The feature is expected to be available to US users in late March 2025.

The updated indication now includes pediatric patients aged 5 through 11 years.

Patients with metabolic dysfunction-associated steatohepatitis (MASH) receiving 300 mg of vitamin E daily presented improved steatosis, lobular inflammation, and fibrosis stages.

Health care professionals and patients must recognize that rapid administration of adrenaline is the only first-line treatment for anaphylaxis.

If approved, gepotidacin (GSK) will be a new oral agent added to the treatment paradigm for urinary tract infections (UTIs).

Pharmacists must consider drug Interactions, allergies, and comorbidities when treating patients with urinary tract infections (UTIs).

The newly-approved intrauterine device (IUD) prevents pregnancy in people of reproductive potential for up to 3 years.

Although tenofovir amibufenamide and tenofovir disoproxil fumarate (TDF) had similar effects, the former resulted in better renal safety and did not impact lipid levels.

The authors note that this lack of inclusion can leave important safety and efficacy questions unanswered.

The designation is supported by pooled data from 4 clinical trials.

Levonorgestrel-releasing intrauterine devices were not found to increase women’s risks of these conditions.

The FDA-approved treatment did not cause as many adverse events as immunotherapy when treating patients with multi-food allergy.

The long-term durability of response will be evaluated in the B-Sure trial (NCT04954859), which will enroll patients with hepatitis B virus (HBV) from B-Together (NCT04676724).